Financial reports
ARS
2023 FY
Annual report to shareholders
25 Apr 24
10-K
2023 FY
Annual report
26 Feb 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q1
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
10-K
2022 FY
Annual report
27 Feb 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
Current reports
8-K
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
26 Feb 24
8-K
Results of Operations and Financial Condition
9 Jan 24
8-K/A
Financial Statements and Exhibits
22 Dec 23
8-K
Completion of Acquisition or Disposition of Assets
9 Nov 23
8-K
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
6 Nov 23
8-K
Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112
1 Nov 23
8-K
Regulation FD Disclosure
23 Oct 23
8-K
Other Events
13 Oct 23
8-K
Departure of Directors or Certain Officers
5 Sep 23
8-K
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
8 Aug 23
Registration and prospectus
S-3ASR
Automatic shelf registration
4 Mar 24
S-8
Registration of securities for employees
26 Feb 24
8-A12B
Registration of securities on exchange
15 Nov 23
425
Business combination disclosure
1 Nov 23
425
Business combination disclosure
23 Oct 23
424B3
Prospectus supplement
29 Sep 23
S-4
Registration of securities issued in business combination transactions
13 Sep 23
425
Business combination disclosure
1 Aug 23
425
Business combination disclosure
1 Aug 23
Proxies
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
DEFA14A
Additional proxy soliciting materials
1 Nov 23
DEFM14A
Proxy related to merger
29 Sep 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEF 14A
Definitive proxy
26 Apr 22
DEFA14A
Additional proxy soliciting materials
3 May 21
DEFA14A
Additional proxy soliciting materials
28 Apr 21
Other
CERT
Certification of approval for exchange listing
16 Nov 23
EFFECT
Notice of effectiveness
2 Oct 23
CORRESP
Correspondence with SEC
27 Sep 23
UPLOAD
Letter from SEC
20 Sep 23
EFFECT
Notice of effectiveness
4 Feb 21
CORRESP
Correspondence with SEC
1 Feb 21
CORRESP
Correspondence with SEC
1 Feb 21
UPLOAD
Letter from SEC
25 Jan 21
EFFECT
Notice of effectiveness
9 Jul 20
CORRESP
Correspondence with SEC
6 Jul 20
Ownership
4
MARK A GOLDSMITH
12 Apr 24
4
Sushil Patel
12 Apr 24
144
Notice of proposed sale of securities
10 Apr 24
144
Notice of proposed sale of securities
10 Apr 24
144
Notice of proposed sale of securities
10 Apr 24
144
Notice of proposed sale of securities
10 Apr 24
3
Lin Wei
29 Mar 24
4
Jeff Cislini
28 Mar 24
144
Notice of proposed sale of securities
27 Mar 24
4
Jeff Cislini
20 Mar 24